Last updated on April 17, 2014 at 13:40 EDT

Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco

January 26, 2012

QUÉBEC CITY, Jan. 26, 2012 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the “Company”) today announced that Jacek Pinski, MD,
PhD, Associate Professor of Medicine at the Norris Comprehensive Cancer
Center of the University of Southern California, will present updated
interim results from a Phase 1 clinical trial in prostate cancer with
AEZS-108 (zoptarelin doxorubicin), the Company’s targeted cytotoxic
luteinizing hormone releasing hormone (“LHRH”) analog. The presentation
will take place on Thursday, February 2, 2012, during the American Society of Clinical Oncology Genitourinary Cancers Symposium which will be held February 2-4, 2012 in San Francisco.

    Poster D3:      "A Phase 1 trial of AEZS-108 in castration - and
                    taxane-resistant prostate cancer ", S.V. Liu, A.V.
                    Schally, T.B. Dorff, D.D. Tsao-Wei, S.G. Groshen, S.
                    Xiong, D. Hawes, D.I. Quinn, Y.C. Tai, N.L. Block, J.
                    Engel, J. K. Pinski

    Presenter:      Jacek Pinski, MD, PhD

    Session:        General Poster Session A: Prostate Cancer

    Date and time:  Thursday, February 2, 2012, 11:45 a.m. - 1:15 p.m.

    Venue:          Golden Gate Hall, San Francisco Marriot Marquis

About AEZS-108

AEZS-108 (zoptarelin doxorubicin) represents a new targeting concept in
oncology using a hybrid molecule composed of a synthetic peptide
carrier and a well-known chemotherapy agent, doxorubicin. AEZS-108 is
the first intravenous drug in a clinical study that directs the
chemotherapy agent specifically to LHRH-receptor expressing tumors,
resulting in more targeted treatment with less damage to healthy
tissue. The product has successfully completed Phase 2 studies for the
treatment of endometrial and ovarian cancer, and is also in Phase 1/2
trials in prostate and bladder cancer. AEZS-108 has been granted
orphan-drug designation by the FDA and orphan medicinal product
designation from the EMA for the treatment of ovarian cancer. Aeterna
Zentaris owns the worldwide rights to AEZS-108.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, multiple myeloma, endometrial, ovarian, prostate
and bladder cancer. The Company’s innovative approach of “personalized
medicine” means tailoring treatments to a patient’s specific condition
and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn
from its proprietary discovery unit providing the Company with constant
and long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com


Source: PR Newswire